My fight to unlock cannabis and psychedelic drugs for use in medical research

Physician Sue Sisley battles to study cannabis and psilocybin mushrooms for pain, addiction and PTSD

Sue Sisley’s team has grown whole psilocybin-producing mushrooms for clinical trials.Credit: Andrew Neugebauer/STOKE Creative

Working scientist profiles

This article is part of an occasional series in which Nature profiles scientists with unusual career histories or outside interests.

From the earliest days of her career, physician Sue Sisley has been passionate about caring for US military veterans. Back then, many of the people she treated were self-medicating with black-market cannabis because, unlike prescription drugs, marijuana allayed nightmares and other symptoms of post-traumatic stress disorder (PTSD). A few puffs helped them to fall asleep.

“Initially, I discouraged them and rolled my eyes thinking about it,” says Sisley, whose training taught her to view only approved drugs as medicines. “I lacked sympathy for their claims and thought they were drug seekers.”

But over time, Sisley saw how the ineffectiveness of mental-health treatments could fuel hopelessness. Currently, 17 US veterans die by suicide daily, on average. The cannabis users among Sisley’s patients were often the ones who maintained a will to live.

“It made me realize that I was very misled, by the government and our training programmes, to believe that cannabis was dangerous,” she says. “I didn’t learn about any medical benefits.”

The early lessons from her patients influenced Sisley. Over the next two decades, she challenged US federal agencies, navigated a legal and regulatory maze and creatively secured funding to investigate and develop treatments, based on cannabis and psychedelics, that the US government had blocked for decades.

A physician-researcher is born

After the US Congress passed the Controlled Substances Act of 1970, cannabis was made illegal and classified as a Schedule I drug, defined as having no accepted medical use. That put marijuana in the same category as heroin and most psychedelic drugs: possession or use of the drug, and growing cannabis without a Schedule I research licence, could land someone in prison.

In the mid-1990s, several US states began defying federal law, allowing adults to purchase cannabis for medicinal purposes. In 2008, when medical marijuana was still off limits in Arizona, Sisley was one of the few physicians who spoke publicly about legalizing it. Her advocacy caught the attention of Rick Doblin, who sought to get certain psychedelic drugs and cannabis taken off Schedule I so that they could be studied and any medical benefits reaped.

Sisley (centre) visits the Texas state capitol to advocate for research on psychedelics.Credit: Andrew Neugebauer/STOKE Creative

Doblin founded a US non-profit body, the Multidisciplinary Association for Psychedelic Studies (MAPS), to raise money from private donors for clinical trials. He approached Sisley to lead a cannabis study.

Although she lacked a background in research, Sisley was an associate professor of psychiatry and assistant director of telemedicine at the University of Arizona College of Medicine in Phoenix, and Doblin saw her potential. “What really appealed to me is that Sue looks to where science is being blocked by politics, and she’s willing to stand up for what she thinks is right,” he says.

In 2014, Sisley and MAPS received nearly US$2.2 million from the state of Colorado. With approval from the US Food and Drug Administration (FDA), they were poised to lead the world’s first randomized controlled trial of smoked cannabis as a treatment for PTSD in veterans.

But then the University of Arizona declined to renew Sisley’s contract. Although Sisley says that the university simply stated that her services were no longer needed, she thinks there were political pressures involved.

“Even though it was legitimate research” and Arizona voters had approved the medical use of marijuana in 2010, Sisley says, “I believe some legislators did not want anything related to cannabis to have a place at the university.”

In the end, however, the termination of her contract “turned out to be a huge gift”, she says. She learnt that she didn’t need a university or hospital to lead the research. In fact, she now thinks the bureaucracy might have slowed her down. In the following two years, Sisley co-founded the Scottsdale Research Institute, purchased a building for it in Phoenix, Arizona, and built a laboratory to begin her study.

In 2016, as she prepared to enrol participants, the cannabis for the study arrived. At the time, the University of Mississippi in Oxford was the sole US government-approved provider of cannabis for use in human research. But when Sisley opened the box, she was horrified. The cannabis was mouldy, pulverized into powder and littered with twigs. It was nothing like the buds sold at dispensaries, and some participants had difficulty in inhaling it because it irritated their throats.

Sisley’s team found that participants who smoked cannabis showed improvement over the placebo group, but not enough to demonstrate statistical significance (M. O. Bonn-Miller et al. PLoS ONE 16, e0246990; 2021). Sisley thought that if participants had access to the cannabis available in dispensaries, they might have tolerated it better and experienced more benefits.

To raise awareness about barriers to cannabis research, Sisley went on a speaking tour (together with Dodger, her guide dog). In 2019, at the South by Southwest conference on music, film, culture and technology in Austin, Texas, she described what was, by then, a ten-year battle to complete her clinical trial, and a move by the US Drug Enforcement Administration (DEA) that might help. In 2016, the agency had announced a policy that aimed to broaden the government’s cannabis supply, so Sisley applied for a Schedule I licence to grow cannabis for a phase IIb trial. But, after two-and-a-half years, the DEA still had not processed her application.

Suing the government for science

Matthew Zorn, an attorney based in Houston, Texas, attended Sisley’s talk. He had become interested in marijuana as a pain treatment while caring for his partner, who later died of bone cancer, and was angered by the red tape surrounding the drug supply for trials. “All Sue was trying to do was advance research. She did everything by the book,” says Zorn. If the cannabis used in a trial “is garbage, of course you can’t prove something is safe and efficacious, and then it’s not going to be available for patients”.

Zorn recruited his colleague Shane Pennington, then also based in Houston, who had experience of bringing cases against federal agencies. Together, representing Sisley pro bono, they helped her to sue the DEA in 2019.

Sue Sisley speaks at the 2025 South by Southwest festival in Austin, Texas.Credit: Andrew Neugebauer/STOKE Creative

The lawsuit prompted the US Office of Legal Counsel to release a memo that revealed why the DEA had been sitting on Sisley’s cannabis application. The US government had handed over control of the cannabis supply for medical trials to the University of Mississippi when, under the terms of an international treaty, it was supposed to ensure that a single government agency possessed and distributed the supply.

With the memo’s release, “they realized they had to do something”, says Anthony Coulson, former assistant special agent in charge of the DEA’s district office in Tucson, Arizona. “Sisley’s lawsuit forced the DEA to the table.”

Two months after the lawsuit was filed, the DEA began processing Sisley’s application and dozens from other US scientists, allowing them to grow medical-grade cannabis for research studies. This was crucial, because cannabis used in phase III trials must match what’s on the market for patients, whereas the government’s supply of cannabis did not.

“Because of Sue’s years of sacrifice, she built a foundation for every single cannabis researcher,” says Coulson.

Sisley’s case was settled in 2020, and she feels the struggle was worth it (see ‘Quick-fire Q&A’). “There are so many people suffering who might get their lives back and benefit from this research.”

Quick-fire Q&A

As a researcher with impaired vision, how have you navigated challenges?

I’ve had low vision since birth. I’m high functioning, but I don’t think anybody expected me to get through medical school. I use guide dogs and can get around, but the biggest challenge is reading. Thank God for all these accessibility devices on my computer and phone. I use the magnifying features to expand documents. It gets tedious, but I just keep moving forward and I surround myself with people who can help to fill in the deficits.

What makes the legal struggles and advocacy work worthwhile?

For years, I wrote conventional prescriptions and never felt as if I was improving people’s lives in the long term. Patients experience side effects, can’t get off their medications or face withdrawal symptoms. Now, I feel joy seeing some people take psychoactive drugs and experience an immediate reduction in symptoms, and an enduring benefit. I hope this research provides tools and maybe interventions that could help to stabilize the illnesses I work on. We still need deep investigations across a much larger population size, but I feel we’re on an important path to helping people.

You treat people receiving hospice care today. What inspired that shift and how might psychedelic research help them?

My dad was a hospice patient who died of end-stage colon cancer. Knowing he would leave our family early created a profound existential distress which didn’t respond to medications such as antidepressants. He was in non-stop pain. It was a brutal death. My mum had dementia, and didn’t want to die like that. She took microdoses of psilocybin and LSD, and her sadness and anxiety melted away. That was the closest thing I’ve ever seen to a good death. Working with people in hospice care, I hope to create change from within and show that psychedelic medicines could have a role.

Around this time, Sisley heard from people who were self-administering the drug psilocybin, found in certain mushrooms, to treat conditions such as cluster headaches and suicidality. She began reading up on psilocybin therapy and learnt that just a few sessions could suppress PTSD symptoms for months or years, although participants had to meet with therapists to prepare for and learn from their psychedelic experiences. By contrast, people typically smoke cannabis daily to maintain its effects.

After Sisley received her cannabis Schedule I licence, she quickly filed an application to farm psilocybin-producing mushrooms. The DEA approved it immediately and “seemed to be cheering for us”, says Sisley.

Coulson has a theory about why the agency — which not only enforces drug laws but also has a core value of enhancing public health — might now be on Sisley’s side. “They want her to succeed because she is driven to move the science forward by a greater altruistic motive of helping patients,” he says. “Once you get to know her, you realize there’s no outside agenda. That’s the magic with Sue.” Since he retired from the DEA in 2010, he has acted as a consultant for Sisley while she built the infrastructure for her studies.

A quest to study natural medicines

In current psilocybin clinical trials, participants receive a synthetic version of the drug that offers precise dosing, which appeals both to the FDA and to pharmaceutical companies.

But Sisley is eager to change that. She wants to study whole mushrooms to investigate whether the diverse chemicals in them provide health benefits. She also sees potential to develop more-affordable treatments, because mushrooms can be grown inexpensively.

Now, Sisley is striving to lead the world’s first FDA-approved study of whole mushrooms containing psilocybin. But once again, she has had to overcome several obstacles.

First, she had to work out how to deliver mushrooms to meet the FDA’s dosing standards. But there was no published protocol for this.

Nicole Nichols, executive director of the Scottsdale Research Institute, grows edible mushrooms and volunteered to develop such a protocol. Initially, she and Sisley tried delivering mushrooms in a warm tea, but the results were erratic. Then they tried using pills, but realized that it would take 18 capsules to deliver the required dose.

Eventually, they experimented with chocolate, which masked the mushrooms’ unpalatable flavour and served as a protective wrap that stabilized psilocybin. After consistently hitting the FDA’s dosing requirements, they published their protocol (R. Goff et al. Anal. Chim. Acta 1288, 342161; 2024).

“We’re getting inquiries from investigators all over the world who want access to federally legal mushrooms that are standardized,” says Sisley.